Forecasts

Neglectedness: A comprehensive search across Metaculus, Polymarket, INFER, Good Judgment Open, and Manifold on March 31, 2026, revealed no active forecasting markets or questions specifically tracking S. 3741 or its core mandates. While the general topic of biosecurity is covered, this specific legislative indicator is currently a gap in systematic monitoring. Monitoring is currently limited to legislative trackers and think-tank policy alerts (e.g., NTI, AIP, and Center for Health Security).

Tractability: Forecasting this question requires synthesizing political dynamics, committee leadership incentives (Cotton/Klobuchar), and industry lobbying AI Can Already Evade DNA Synthesis Screening. Congress's New ... All Info - S.3741 - 119th Congress (2025-2026): Biosecurity .... While there is a rich information environment of legislative history and expert analysis, the synthesis of these signals to predict a binary outcome (signed vs. not) is non-trivial for a researcher.

Soon: The bill was introduced in January 2026 and is currently active in the 119th Congress All Info - S.3741 - 119th Congress (2025-2026): Biosecurity .... Given the resolution deadline of December 31, 2026, the question tracks a development at a critical juncture where the legislative window is open and the outcome will be determined within the required timeframe.

Sudden: Legislative passage is a discrete state change (signed into law). While the committee process (Commerce, Science, and Transportation) is visible All Info - S.3741 - 119th Congress (2025-2026): Biosecurity ..., the final passage often involves sudden movements, such as attachment to larger 'must-pass' spending packages, which can happen with limited advance public warning.

Sharp: The risk of misused synthetic DNA follows a pattern where a single consequential incident could occur without smaller 'warning shots' that trigger policy change, making proactive regulation like S. 3741 particularly important AI Can Already Evade DNA Synthesis Screening. Congress's New .... However, the bill itself is a response to the known potential for such incidents rather than a direct response to a specific 'warning shot' event.

Will the 'Biosecurity Modernization and Innovation Act of 2026' (S. 3741), or a successor bill containing its core gene synthesis screening mandates, be signed into law by the President of the United States on or before December 31, 2026?

Why this question? The paper identifies a critical regulatory gap where current U.S. DNA synthesis screening is largely voluntary [ad2493]. The Biosecurity Modernization and Innovation Act, introduced in February 2026 by Senators Cotton and Klobuchar, represents the primary legislative attempt to close this gap by mandating screening for all synthetic DNA orders [d55ce2]. This question tracks the transition from a voluntary to a mandatory 'Swiss-cheese' layer of defense.

Paper reference: Section 3: Conclusion (part 19-21), Biosecurity Modernization and Innovation Act of 2026 (S. 3741)

Quality: 88.0   Ambiguity: 90.0

Quality notes: This is a high-quality forecasting question. It addresses a genuinely uncertain and non-trivial political event (passage of S. 3741) with a clear binary resolution criterion Biosecurity Modernization and Innovation Act of 2026 is a Major Step S.3741 - Biosecurity Modernization and Innovation Act of 2026 .... The inclusion of 'successor bill containing its core gene synthesis screening mandates' allows for legislative evolution while remaining researchable S.3741 - Biosecurity Modernization and Innovation Act of 2026 .... The bill's bipartisan support but uncertain legislative path creates high entropy Biosecurity Modernization and Innovation Act of 2026 is a Major Step AI Can Already Evade DNA Synthesis Screening. Congress's New .... Verification is straightforward via Congress.gov S.3741 - Biosecurity Modernization and Innovation Act of 2026 ....

Ambiguity notes: checklist 1. True - Terms like 'core gene synthesis screening mandates', 'successor bill', and 'gene synthesis' are precisely defined in the 'Definitions' and 'Resolution Criteria' sections S.3741 - Biosecurity Modernization and Innovation Act of 2026 .... 2. True - The resolution time is specified as 11:59 PM UTC on December 31, 2026. 3. Does not apply - No numeric thresholds are used. 4. True - The definition of 'successor bill' based on specific mandates (Sequence-based screening, KYC, Conformity Assessment) protects against the question becoming unresolvable if the bill is incorporated into an omnibus package S.3741 - Biosecurity Modernization and Innovation Act of 2026 .... 5. 90 - Congress.gov is the definitive source for legislative status. While identifying the mandates in a successor bill requires some textual analysis, the criteria are sufficiently objective. additional comments The definition of 'successor bill' is a strong feature that makes this question resilient to legislative maneuvering. Specifying 'signed into law' to include the 10-day rule and veto overrides is also excellent practice. final_answer_reasoning The question is clear and relies on objective legislative milestones. The core mandates are defined with enough specificity that their presence in a bill can be verified via the official text on Congress.gov. final_answer great

Assessment: NEEDS_REVISION   Edge case risk: MEDIUM

ASSESSMENT: NEEDS_REVISION REVIEW: The forecasting question is well-defined structurally but contains substantive issues regarding the current policy landscape and the bill's actual content. 1. Misalignment with Bill Text: There is a discrepancy in how the bill is characterized. While the question defines "core mandates" as sequence screening, KYC, and auditing S.3741 - Biosecurity Modernization and Innovation Act of 2026 ..., some policy analyses (e.g., from the Federation of American Scientists) describe S. 3741 primarily as an assessment and planning bill designed to identify gaps rather than a direct mandate for these specific technical requirements Biosecurity Modernization and Innovation Act of 2026 is a Major Step. If the bill passes in its current form as a "study and report" bill, it would resolve as 'No' under the current criteria despite the bill itself being signed into law. 2. Executive Order Overlap: A major Executive Order (EO) signed on May 5, 2025, titled 'Improving the Safety and Security of Biological Research,' already mandates many of these practices for federally funded research and explicitly directs the administration to develop a 'legislative proposal' to close gaps for non-federally funded synthesis Improving the Safety and Security of Biological Research. This makes the introduction of S. 3741 (on January 29, 2026) a likely byproduct of an existing administrative mandate rather than an independent legislative effort S.3741 - Biosecurity Modernization and Innovation Act of 2026 .... This significantly lowers the uncertainty for forecasters who are aware of the EO. 3. Successor Bill Ambiguity: The 'successor bill' definition is overly broad. It allows the question to resolve 'Yes' if these three mandates are tucked into any large omnibus package (like the NDAA), which is a common legislative tactic Cotton, Klobuchar Introduce Bill to Establish Federal Biotech .... This shifts the forecast from 'Will this biosecurity policy pass?' to 'Will any major must-pass bill include these provisions?', which measures a different type of political uncertainty. 4. Technical Specifics: The bill's reliance on 'sequences of concern' to be defined later by the Secretary of Commerce creates a 'moving target' for resolution. The question lacks a clear definition of 'covered providers,' which is essential to determine if the mandates apply to the whole industry or just a subset Cotton, Klobuchar Introduce Bill to Establish Federal Biotech .... EVIDENCE: https://www.congress.gov/bill/119th-congress/senate-bill/3741, https://www.whitehouse.gov/presidential-actions/2025/05/improving-the-safety-and-security-of-biological-research/, https://fas.org/publication/biosecurity-modernization-and-innovation-act-of-2026/ SUGGESTION: 1. Clarify the 'Successor Bill' definition to require that the primary purpose of the legislation remains biosecurity or synthetic biology oversight. 2. Update the background to acknowledge the May 5, 2025 Executive Order, as this is the primary driver for the legislation. 3. Ensure the resolution criteria align with the actual text of S. 3741; if the bill is a 'study and report' vehicle, the question should reflect whether the study is mandated, or specify that only a bill with enforceable mandates (as currently defined) counts. 4. Add a definition for 'covered providers' to the background to clarify the regulatory scope.

The question is substantively well-posed and resolvable, and 12% is reasonable. The status-quo case dominates: a complex regulatory bill in committee, no House companion, ~11 months left in a midterm year, with the BIOSECURE Act precedent (23 months, still unenacted). The resolution bar is also demanding — the enacted text must carry enforceable mandates (not studies) across all three pillars, which a watered-down or omnibus version may fail even if 'a biosecurity bill' passes. That pushes me slightly below the pipeline, ~8-10%, with the main YES path being NDAA attachment. Not a material disagreement. Two flaws to flag: (1) a deadline conflict — title/criteria say Dec 31 2026 but the RESOLUTION DEADLINE field says Dec 31 2027; a 2027 deadline (two NDAA cycles) would justify a materially higher probability, so this must be reconciled. (2) Text corruption: a stray '海' character appears in 'This海 question'.

Suggested question fix: Reconcile the deadline: confirm the operative date is December 31, 2026 in both the criteria and the RESOLUTION DEADLINE field (currently 2027). Remove the stray '海' character in 'This海 question will resolve'.

Neglectedness: A search of Metaculus, Polymarket, Manifold, INFER, and Good Judgment Open confirms no active forecasting questions or markets specifically track the finalization of the 'Framework for Nucleic Acid Synthesis Screening' or its specific screening mandates. While the general topic of DNA synthesis is discussed in policy circles FAQs | Gene Synthesis Screening Information Hub HHS & OSTP Screening | Synthetic Nucleic Acid Security & Biorisk ..., this specific regulatory milestone is not being systematically monitored by the forecasting community. Some think tanks like the Center for Health Security and SPAR track related policy, but do not provide formal probabilistic forecasts on this outcome FAQs | Gene Synthesis Screening Information Hub HHS & OSTP Screening | Synthetic Nucleic Acid Security & Biorisk ... H.R.3029 - 119th Congress (2025-2026): Nucleic Acid Standards for ....

Tractability: This is a highly tractable forecasting task. It requires synthesizing evidence from executive orders, legislative status (e.g., H.R. 3029), and official agency announcements from HHS and OSTP Improving the Safety and Security of Biological Research H.R.3029 - 119th Congress (2025-2026): Nucleic Acid Standards for ... FAQs | Gene Synthesis Screening Information Hub. Skilled forecasters can improve on a naive prior by analyzing the tension between the 2025 EO's mandates and the administrative delays observed in late 2025 and early 2026 HHS & OSTP Screening | Synthetic Nucleic Acid Security & Biorisk ... FAQs | Gene Synthesis Screening Information Hub.

Soon: The outcome will be locked in within the window (ending Dec 31, 2026), as the May 2025 Executive Order (EO 14292) set a 90-day deadline for revision Improving the Safety and Security of Biological Research FAQs | Gene Synthesis Screening Information Hub. Current status reports from March 2026 indicate the framework is still in the 'revision/replacement' phase, making the 2026 deadline a critical juncture for confirming implementation HHS & OSTP Screening | Synthetic Nucleic Acid Security & Biorisk ... FAQs | Gene Synthesis Screening Information Hub.

Sudden: While the policy process is visible, the final publication and the specific stringency of the mandate (e.g., 'screen all orders') could be announced suddenly HHS & OSTP Screening | Synthetic Nucleic Acid Security & Biorisk .... However, the overall direction of travel is broadly visible due to the 2025 Executive Order Improving the Safety and Security of Biological Research FAQs | Gene Synthesis Screening Information Hub.

Sharp: The question tracks a regulatory process, which typically involves 'warning shots' like draft frameworks or public comment periods HHS & OSTP Screening | Synthetic Nucleic Acid Security & Biorisk ... H.R.3029 - 119th Congress (2025-2026): Nucleic Acid Standards for .... However, the 'sharp' aspect lies in the biosecurity risk it mitigates: the first observable failure (a synthesized pathogen) could be the consequential incident itself, and this policy seeks to prevent that silent compounding of risk Improving the Safety and Security of Biological Research HHS & OSTP Screening | Synthetic Nucleic Acid Security & Biorisk ....

By December 31, 2026, will the U.S. Department of Health and Human Services (HHS) or the Office of Science and Technology Policy (OSTP) publish a final, updated "Framework for Nucleic Acid Synthesis Screening" that requires federally funded institutions to only purchase from providers that screen all orders?

Why this question? The paper identifies "ordering from DNA synthesis companies who don't screen" as a primary fear. A updated framework is currently being revised following a May 2025 Executive Order [9b9597]. This question tracks a critical regulatory milestone that would address the "institutional and coordinative" bottlenecks mentioned in the paper.

Paper reference: Conclusion, Page 66-67: "ordering from DNA synthesis companies who don't screen" and the need for "comprehensive coverage."

Quality: 90.0   Ambiguity: 95.0

Quality notes: This is an excellent forecasting question. It tracks a specific regulatory milestone mandated by Executive Order 14292 (May 5, 2025), which required OSTP to revise the 'Framework for Nucleic Acid Synthesis Screening' Improving the Safety and Security of Biological Research. As of March 2026, the 90-day deadline from the EO has long passed, yet official HHS/ASPR resources indicate the framework is still in the process of being updated HHS & OSTP Screening | Synthetic Nucleic Acid Security & Biorisk .... This creates a high-entropy situation where the timing of the 'final' publication is genuinely uncertain. The question is objective, verifiable via government publications, and addresses a critical policy bottleneck identified in the source literature.

Ambiguity notes: checklist 1. True - Key terms like 'Federally Funded Entities' and 'Non-Federal entities' are explicitly defined with links to 2 CFR § 200.1 https://aspr.hhs.gov/S3/Pages/Synthetic-Nucleic-Acid-Screening.aspx. 'Comprehensive screening' and 'Sequences of Concern' (SOCs) are also defined with technical standards. 2. True - The resolution time is clearly stated as 23:59 UTC on December 31, 2026. 3. Does not apply - There are no specific numeric thresholds mentioned; the criteria rely on explicit regulatory language (e.g., 'only' or 'exclusively'). 4. True - The question is robust; it explicitly excludes 'Draft for Public Comment' versions and defines 'successor documents' to ensure it captures the final policy action regardless of title changes https://aspr.hhs.gov/S3/Pages/Synthetic-Nucleic-Acid-Screening.aspx. 5. 95 - The resolution source (HHS/ASPR and OSTP official sites) is official and unambiguous. The requirement for 'explicit' language in the published framework minimizes interpretive subjectivity. additional comments The question is exceptionally well-defined. It correctly anticipates the difference between draft and final versions and provides a clear technical baseline for what constitutes 'comprehensive screening.' final_answer_reasoning The question provides precise definitions for all critical terms and uses reliable official government sources. The criteria for a 'YES' resolution are objective and clearly stated, leaving very little room for disagreement between reasonable observers. final_answer great

Assessment: NEEDS_REVISION   Edge case risk: MEDIUM

ASSESSMENT: NEEDS_REVISION REVIEW: The forecasting question requires revision because its primary condition—that federally funded entities must purchase only from compliant providers—is already a feature of the existing September 2024 Framework [[PDF] Framework For Nucleic Acid Synthesi Screening](https://aspr.hhs.gov/S3/Documents/OSTP-Nucleic-Acid-Synthesis-Screening-Framework-Sep2024.pdf). Section II of the 2024 Framework explicitly states that federal funding agencies will require 'synthetic nucleic acid procurement for federally funded research is conducted through Providers or Manufacturers that adhere to the framework,' a requirement that took effect on April 26, 2025 [[PDF] Framework For Nucleic Acid Synthesi Screening](https://aspr.hhs.gov/S3/Documents/OSTP-Nucleic-Acid-Synthesis-Screening-Framework-Sep2024.pdf). While Executive Order 14292 (issued May 5, 2025) does mandate a revision or replacement of this framework Improving the Safety and Security of Biological Research, the specific 'mandatory' purchasing requirement described in the resolution criteria is already active policy under the 2024 version. Consequently, a 'YES' resolution could be triggered by a document that merely restates existing requirements rather than introducing the intended 'more rigorous approach' mentioned in the background. Additionally, the technical definition of 'comprehensive screening' in the question matches the 'Best Match' homology search already recommended in the 2023 and 2024 guidance [[PDF] Screening Framework Guidance for Providers and Users of ...](https://aspr.hhs.gov/S3/Documents/SynNA-Guidance-2023.pdf) [[PDF] Framework For Nucleic Acid Synthesi Screening](https://aspr.hhs.gov/S3/Documents/OSTP-Nucleic-Acid-Synthesis-Screening-Framework-Sep2024.pdf). To be a meaningful forecast, the question needs to distinguish the new requirements sought by the 2025 Executive Order (such as 'verifiable' screening or specific enforcement mechanisms) from the baseline established in 2024. EVIDENCE: https://aspr.hhs.gov/S3/Documents/OSTP-Nucleic-Acid-Synthesis-Screening-Framework-Sep2024.pdf, https://www.whitehouse.gov/presidential-actions/2025/05/improving-the-safety-and-security-of-biological-research/, https://aspr.hhs.gov/S3/Documents/SynNA-Guidance-2023.pdf SUGGESTION: Revise the resolution criteria to focus on the novel elements mandated by Executive Order 14292 that are not in the 2024 Framework. Specifically, require that the updated framework include 'verifiable' screening mechanisms or the specific 'enforcement mechanisms' described in Section 7 of EO 14292. Alternatively, pivot the question to focus on the inclusion of specific new technical standards (e.g., screening against 'functional' attributes rather than just homology) or the expansion of the 'Sequences of Concern' list to include specific AI-generated or synthetic threats mentioned in the 2025 Order.

Given that the 2024 framework successfully encompassed all three categories, and that Executive Order 14292 seeks to strengthen rather than weaken these rules, it is highly improbable that the updated framework would regress to excluding RNA or ssDNA ^[4].

Applicability to Non-Federal Entities The applicability of the framework is intrinsically tied to the mechanisms of federal funding. The stated policy goal is to manage risks associated with federally funded life sciences research by imposing conditions on grant recipients ^{[4, 11]}. Under Title 2 of the Code of Federal Regulations governing federal grants (2 CFR § 200.1), "Non-Federal entities" encompass state governments, local governments, Indian Tribes, universities (Institutions of Higher Education), and nonprofit organizations carrying out a Federal award ^{[14, 15]}. The primary enforcement lever of the framework is to restrict these Non-Federal entities from using federal funds to procure nucleic acids from unverified, non-compliant providers ^{[7, 11]}. Therefore, the framework's core operational mechanism inherently satisfies the applicability criterion.

The "Privately Funded" Loophole

While the framework will fulfill the applicability criteria regarding Non-Federal entities, a critical gap in current biosecurity governance is that corporate labs, privately funded pharmaceutical companies, or independent rogue actors who do not receive federal grants are entirely exempt from the HHS/OSTP framework's requirements ^{[16, 17]}. Because they do not rely on federal funding strings, these actors can simply bypass the system by purchasing synthetic nucleic acids from non-compliant providers. This loophole fundamentally undermines the centralized screening chokepoint and is a primary driver behind current bipartisan legislative efforts to move beyond the executive branch framework and mandate screening industry-wide ^{[18, 19]}.

Catalysts for Action: Legislative Pressure and Industry Consensus in 2026

While bureaucratic inertia is a strong base-rate factor explaining the delay since the August 2025 deadline, the landscape in early-to-mid 2026 has fundamentally shifted. A convergence of bipartisan legislative action and unprecedented lobbying from the commercial tech sector has created an environment where further delays by the OSTP and HHS are politically untenable.

The Biosecurity Modernization and Innovation Act (S. 3741)

In early 2026, Senators Tom Cotton (R-AR) and Amy Klobuchar (D-MN) introduced the Biosecurity Modernization and Innovation Act of 2026 (S. 3741) ^{[20, 21]}. This bipartisan legislation serves as a massive catalyst for executive action.

Provisions of S. 3741 The legislation essentially codifies the goals of the paused OSTP framework and Executive Order 14292 into federal law, pushing the boundaries of biosecurity requirements:

1. Mandatory Screening and Verification: It requires gene synthesis providers to screen orders and verify the identity and legitimacy of customers ^{[20, 22]}.
2. Conformity Assessments: It establishes a conformity assessment system, shifting the industry away from self-attestation toward rigorous, verifiable compliance checks that can result in the revocation of a provider's approved status ^[20].
3. Addressing the "Split Order" Vulnerability: It specifically addresses technical loopholes, such as bad actors splitting dangerous sequences across multiple orders or providers (e.g., ordering a viral capsid sequence from Provider A and the viral polymerase sequence from Provider B to bypass individual screening algorithms) ^{[7, 23]}. Offline or air-gapped benchtop synthesis devices are also highly vulnerable to these split-order evasion tactics ^{[24, 25]}. S. 3741 addresses this by requiring cross-provider screening protocols and centralized databases ^{[25, 26]}.
4. Biotechnology Governance Sandbox: The bill establishes a sandbox at the National Institute of Standards and Technology (NIST) to test biosecurity tools and advance technical standards ^{[20, 22]}.

The introduction of S. 3741 places significant pressure on the OSTP and HHS. The Executive Branch traditionally prefers to establish regulatory frameworks through executive agencies rather than having its hand forced by rigid congressional statutes. The presence of S. 3741 accelerates the OSTP's timeline, as publishing a robust, finalized framework can preempt or guide the implementation of the pending legislation.

The AI Industry's June 2026 Open Letter

Perhaps the most compelling evidence for a late-2026 publication is the sudden, unified involvement of the artificial intelligence industry. In early June 2026, an open letter organized by the Foundation for American Innovation (FAI) was released, featuring signatures from the most powerful executives in the technology sector ^{[27, 28, 29]}.

Signatories included OpenAI CEO Sam Altman, Anthropic CEO Dario Amodei, Google DeepMind CEO Demis Hassabis, and Microsoft AI CEO Mustafa Suleyman ^{[27, 28, 30]}. These executives, who are fierce commercial rivals, united to explicitly urge Congress and the federal government to mandate synthetic DNA and RNA screening ^{[28, 31]}.

The Rationale of the AI Sector The AI leaders argued that generative AI models are rapidly eroding the "knowledge barriers" that historically prevented unsophisticated bad actors from designing and deploying biological weapons ^{[30, 32]}. AI systems can now outperform PhD-level virologists in answering highly technical biological questions and can generate thousands of hazardous protein variants capable of bypassing rudimentary screening systems ^{[31, 33]}.

By publicly supporting mandatory screening, record-keeping, and the verification of customer legitimacy, the tech industry effectively removed one of the primary obstacles to regulation: corporate pushback over compliance costs. Opponents of mandatory screening traditionally argued that the burden of compliance would harm small businesses ^[28]. However, with the largest tech entities and synthetic biology companies (such as those in the International Gene Synthesis Consortium) publicly demanding verifiable regulation, the OSTP has a clear political mandate and an open runway to finalize the framework ^{[29, 31]}.

The October 2026 Technical Standards Deadline

Another critical timeline factor is the impending shift in technical screening standards. Under the original guidelines, providers were required to screen DNA and RNA sequences using a 200-nucleotide window ^{[4, 6]}. However, advances in synthetic biology mean that dangerous pathogens can be assembled from much shorter fragments.

The baseline documentation explicitly notes that starting October 13, 2026, the screening window must decrease from 200 nucleotides to 50 nucleotides ^[6]. The biological necessity of this shift lies in the fact that bad actors can synthesize complete sequences of concern (SOCs) by ordering shorter fragments that preserve important functional elements and assembling them later ^{[34, 35]}. Furthermore, by this October 2026 deadline, the definition of an SOC will expand beyond federally regulated lists to include any sequence known to contribute to pathogenicity or toxicity ^[6]. The approach of this highly specific, pre-scheduled October 2026 technical transition heavily incentivizes the OSTP to publish the finalized, updated framework well in advance of the deadline to ensure that academic institutions and synthesis providers have adequate time to update their bioinformatic software and screening infrastructure ^{[6, 36]}.

Forecasting Analysis: Resolving YES vs. NO

Forecasting the outcome of this query requires weighing the overwhelming political and industry momentum against the base rates of bureaucratic stagnation and the technical complexities of implementing verifiable biosecurity.

The Case for a YES Resolution

The strongest evidence for a YES resolution by December 31, 2026, relies on a confluence of explicit executive text, vanishing industry resistance, and scheduled technical deadlines.

1. Explicit Executive Mandate: The resolution criteria demand the inclusion of verifiable screening or Section 7 enforcement terms. Executive Order 14292 explicitly, verbatim, commands the inclusion of both ^{[9, 11]}. There is virtually no scenario in which the OSTP publishes a "Final" framework that openly disobeys the text of the governing executive order.
2. The "Safe" Regulatory Target: As noted by industry analysts, regulating the physical synthesis of DNA is a highly tractable policy intervention. Compared to the highly contentious debates over regulating open-source AI weights or algorithmic liability, screening physical DNA orders addresses a known, established chokepoint ^[29]. Policymakers seeking a "win" in AI safety and biosecurity will view the framework as low-hanging fruit.
3. The October 2026 Forcing Function: The scheduled drop in the screening window to 50 nucleotides on October 13, 2026, acts as a hard forcing function ^[6]. The federal government cannot reasonably enforce this new technical standard without a finalized framework in place to govern it.
4. Bipartisan and Industry Support: The June 2026 open letter from Altman, Amodei, Hassabis, and Suleyman, combined with the bipartisan S. 3741 bill, eliminates standard partisan gridlock ^{[27, 30]}. The cross-industry consensus ensures that the OSTP will face minimal lobbying resistance upon publication.

The Case for a NO Resolution

While a YES resolution is highly probable, forecasters must account for scenarios in which the question resolves as NO. This would most likely occur due to administrative delays pushing publication into 2027, or a failure of the document to be marked as "Final."

1. The Base Rate of Bureaucratic Delays: The most significant threat to a YES resolution is simple government inefficiency. The OSTP missed its initial 90-day deadline from May 2025 by a wide margin ^{[9, 11]}. (Note: Precise real-time figures regarding the internal drafting status at the OSTP are unavailable; however, the public frustration expressed in legislative and industry letters confirms the framework is severely delayed). It is entirely plausible that interagency disagreements could stall the publication until 2027.
2. The Complexity of "Verifiable" Standards: Transitioning from self-attestation to a mathematically and legally verifiable standard is technically daunting. Resolving how to screen 50-nucleotide sequences efficiently without generating an unmanageable volume of false positives (alert fatigue) requires highly sophisticated bioinformatics ^{[6, 37]}. Standard alignment tools like BLAST often yield high false-positive rates and increased computational costs for short sequences due to shared genes between pathogenic and non-pathogenic organisms ^{[35, 37]}. Advanced predictive bioinformatic algorithms and signature-based detection are required to maintain false-positive rates below 1% or 2% (as demonstrated by emerging tools like RTX BBN's FAST-NA or UltraQUICK) ^{[35, 38, 39]}. If the NIST sandbox takes too long to validate these screening algorithms, the OSTP might delay the final framework until the technical standards are proven ^[22].
3. The "Interim" Trap: The forecasting criteria allow for an "Interim Final" document if it establishes a compliance date. However, if the OSTP releases a "Draft for Public Comment" in late 2026 but fails to publish a final or interim final version before December 31, 2026, the question will resolve as NO.

Final Synthesis

When evaluating the base rates of federal rulemaking, policies involving national security and biological threats historically advance faster than standard domestic regulations, especially when catalyzed by specific executive orders and high-profile industry lobbying. The Trump administration's EO 14292 unequivocally laid the legal groundwork in 2025, defining the exact parameters (Section 7 enforcement, verifiable mechanisms) that this forecasting question seeks ^{[8, 9]}.

Throughout early to mid-2026, the ecosystem surrounding synthetic biology oversight reached a critical mass. Bipartisan lawmakers introduced stringent legislative mandates (S. 3741), and the foremost leaders of the artificial intelligence boom publicly demanded government intervention to secure the nucleic acid supply chain ^{[20, 28]}.

Furthermore, the operational realities of the synthesis industry—specifically the scheduled transition to 50-nucleotide screening windows by October 2026—create an unavoidable logistical deadline for the federal government ^[6]. Benchtop synthesis equipment, while currently limited by lower throughput capabilities (e.g., producing 96 oligos per run) and shorter sequence lengths (up to ~80-100 base pairs), will also require robust regulatory integration as enzymatic synthesis technologies mature ^{[1, 2]}. Providers and federally funded institutions cannot implement these enhanced, costly technical standards without finalized legal guidance clarifying compliance and enforcement risks.

Therefore, it seems highly likely that the intense, multipolar pressure from Capitol Hill, the tech sector, and internal technical deadlines will force the HHS and OSTP to overcome bureaucratic inertia. The evidence strongly leans toward the final, updated "Framework for Nucleic Acid Synthesis Screening" being published before December 31, 2026. Because Executive Order 14292 mandates the inclusion of verifiable screening, Section 7 enforcement, and the baseline encompasses all forms of RNA and DNA, the resulting framework is virtually guaranteed to meet all the nuanced requirements of the resolution criteria.

Sources:

1. substack.com
2. startupintros.com
3. ebrc.org
4. archives.gov
5. ucf.edu
6. hhs.gov
7. frontiersin.org
8. lathropgpm.com
9. federalregister.gov
10. asm.org
11. ucsb.edu
12. psu.edu
13. precisionbusinessinsights.com
14. ecfr.gov
15. tamu.edu
16. longtermresilience.org
17. sciencepolicyjournal.org
18. biosecurityhandbook.com
19. frontiersin.org
20. quiverquant.com
21. legiscan.com
22. mondaq.com
23. centerforhealthsecurity.org
24. ifp.org
25. securedna.org
26. effectivealtruism.org
27. letsdatascience.com
28. qz.com
29. theplanettools.ai
30. wttlonline.com
31. forbes.com
32. aiweekly.co
33. cnet.com
34. nih.gov
35. hhs.gov
36. eurofinsgenomics.com
37. biorxiv.org
38. frontiersin.org
39. centerforhealthsecurity.org

The question is well-posed: conditions 1-3 (enhanced requirements, three-acid coverage, non-federal applicability) are near-certain conditional on publication, since any EO 14292-driven framework would include them and the 2024 baseline already covers all three acid types. So this reduces almost entirely to P(a qualifying 'Final' or 'Interim Final' framework is published in the ~9-month Apr-Dec 2026 window). The pipeline's correlation argument is sound, but 60% leans optimistic. The dominant risk is bureaucratic slippage into 2027: the EO's 90/180-day deadlines were already badly missed, 'verifiable' standards are genuinely hard to finalize, and interagency drafting frequently overruns. The Oct 2026 technical forcing function and Interim Final allowance push upward, but a draft-for-comment (not final) by year-end is a very live NO path. I'd center ~50%. Note: the deep-research report's S. 3741 and June 2026 AI-CEO open letter claims are unverified and should not anchor the estimate. Minor: 'RESOLUTION DEADLINE 31 Dec 2027' conflicts with the Dec 31 2026 window.

Suggested question fix: Align the RESOLUTION DEADLINE field (currently 31 Dec 2027) with the resolution window's end of 23:59 UTC 31 Dec 2026, and remove the stray 'only/exclusively purchase requirement' waiver clarification, which maps to no stated resolution condition.